Patents by Inventor Sandra Bruder
Sandra Bruder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9649374Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: GrantFiled: November 18, 2010Date of Patent: May 16, 2017Assignee: Bayer Intellectual Property GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20160193359Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: February 24, 2016Publication date: July 7, 2016Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif EL SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah Jörißen, Sandra BORKOWSKI
-
Patent number: 9241989Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: GrantFiled: November 18, 2010Date of Patent: January 26, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20150246136Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.Type: ApplicationFiled: May 11, 2015Publication date: September 3, 2015Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Lars LINDEN, Sherif El SHEIKH, Jörg WILLUDA, Charlotte C. KOPITZ, Joachim SCHUHMACHER, Simone GREVEN, Christoph MAHLERT, Beatrix STELTE-LUDWIG, Sven GOLFIER, Rudolf BEIER, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Sandra BRUDER, Heike PETRUL, Hannah JÖRISSEN, Sandra BORKOWSKI
-
Patent number: 8992932Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: GrantFiled: October 20, 2012Date of Patent: March 31, 2015Assignee: Seattle Genetics, Inc.Inventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte Christine Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jöriβen, Sandra Borkowski
-
Publication number: 20150030618Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: May 5, 2014Publication date: January 29, 2015Applicant: SEATTLE GENETICS, INC.Inventors: Hans-Georg LERCHEN, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte C. Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörissen, Sandra Borkowski
-
Publication number: 20150023989Abstract: The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.Type: ApplicationFiled: December 12, 2012Publication date: January 22, 2015Inventors: Hans-Georg Lerchen, Stefanie Hammer, Axel Harrenga, Charlotte Christine Kopitz, Carl Friedrich Nising, Anette Sommer, Beatrix Stelte-Luowig, Christoph Mahlert, Joachim Schuhmacher, Sven Golfier, Simone Greven, Sandra Bruder
-
Publication number: 20140322220Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: November 22, 2012Publication date: October 30, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
-
Publication number: 20140127240Abstract: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.Type: ApplicationFiled: April 20, 2012Publication date: May 8, 2014Applicants: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbHInventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte C. Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörißen, Sandra Brokowski
-
Publication number: 20130272968Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: October 17, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20130171147Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: July 4, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder
-
Publication number: 20130129739Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: May 23, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Ottto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20130122024Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: April 20, 2012Publication date: May 16, 2013Applicant: Bayer Intellectual Property GmbHInventors: Hans-Georg LERCHEN, Beatrix STELTE-LUDWIG, Sven GOLFIER, Charlotte Christine KOPITZ, Rudolf BEIER, Sherif EL SHEIKH, Iring HEISLER, Axel HARRENGA, Karl-Heinz THIERAUCH, Joachim SCHUHMACHER, Sandra BRUDER, Simone GREVEN, Lars LINDEN, Jörg WILLUDA, Christoph MAHLERT, Heike PETRUL, Hannah JÖRIßEN, Sandra Borkowski
-
Publication number: 20130066055Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: April 20, 2012Publication date: March 14, 2013Applicant: Bayer Intellectual Property GmbHInventors: Hans-Georg Lerchen, Lars Linden, Sherif El Sheikh, Jörg Willuda, Charlotte Christine Kopitz, Joachim Schuhmacher, Simone Greven, Christoph Mahlert, Beatrix Stelte-Ludwig, Sven Golfier, Rudolf Beier, Iring Heisler, Axel Harrenga, Karl-Heinz Thierauch, Sandra Bruder, Heike Petrul, Hannah Jörissen, Sandra Borkowski
-
Publication number: 20130022606Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: January 24, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder
-
Publication number: 20120321632Abstract: The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The composition of the invention blocks prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: December 20, 2012Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20120315276Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 002-H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: December 13, 2012Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder